Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up

With the price of drugs front and center in Washington DC these days, Regeneron and Sanofi are attracting kudos for their decision to hold back the price hike on Dupixent to a mere 3%, which the pharma giant notes is well within the rate of medical inflation — their cap on price increases.